Format
Sort by
Items per page

Send to

Choose Destination

Best matches for interleukin 6 parkinson's:

Search results

Items: 1 to 20 of 204

1.

Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia.

Huang MY, Tu CE, Wang SC, Hung YL, Su CC, Fang SH, Chen CS, Liu PL, Cheng WC, Huang YW, Li CY.

BMC Complement Altern Med. 2018 Aug 15;18(1):221. doi: 10.1186/s12906-018-2287-5.

2.

Anti-Neuroinflammatory Effects of Vanillin Through the Regulation of Inflammatory Factors and NF-κB Signaling in LPS-Stimulated Microglia.

Kim ME, Na JY, Park YD, Lee JS.

Appl Biochem Biotechnol. 2018 Aug 10. doi: 10.1007/s12010-018-2857-5. [Epub ahead of print]

PMID:
30097802
3.

Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α.

Li D, Song X, Huang H, Huang H, Ye Z.

Neurosci Lett. 2018 Jul 29;683:181-184. doi: 10.1016/j.neulet.2018.07.027. [Epub ahead of print]

PMID:
30063943
4.

Piperlongumine inhibits neuroinflammation via regulating NF-κB signaling pathways in lipopolysaccharide-stimulated BV2 microglia cells.

Kim N, Do J, Bae JS, Jin HK, Kim JH, Inn KS, Oh MS, Lee JK.

J Pharmacol Sci. 2018 Jun;137(2):195-201. doi: 10.1016/j.jphs.2018.06.004. Epub 2018 Jun 18.

5.

Modulation of M1/M2 polarization by capsaicin contributes to the survival of dopaminergic neurons in the lipopolysaccharide-lesioned substantia nigra in vivo.

Bok E, Chung YC, Kim KS, Baik HH, Shin WH, Jin BK.

Exp Mol Med. 2018 Jul 3;50(7):76. doi: 10.1038/s12276-018-0111-4.

6.

Higher serum levels of pro-hepcidin in patients with Parkinson's disease treated with deep brain stimulation.

Kwiatek-Majkusiak J, Geremek M, Koziorowski D, Tomasiuk R, Szlufik S, Friedman A.

Neurosci Lett. 2018 Jun 18. pii: S0304-3940(18)30434-8. doi: 10.1016/j.neulet.2018.06.031. [Epub ahead of print]

PMID:
29928951
7.

Multi-Target Protective Effects of Gintonin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Mediated Model of Parkinson's Disease via Lysophosphatidic Acid Receptors.

Choi JH, Jang M, Oh S, Nah SY, Cho IH.

Front Pharmacol. 2018 May 23;9:515. doi: 10.3389/fphar.2018.00515. eCollection 2018.

8.
9.
10.

α-Cyperone inhibits LPS-induced inflammation in BV-2 cells through activation of Akt/Nrf2/HO-1 and suppression of the NF-κB pathway.

Huang B, He D, Chen G, Ran X, Guo W, Kan X, Wang W, Liu D, Fu S, Liu J.

Food Funct. 2018 May 23;9(5):2735-2743. doi: 10.1039/c8fo00057c.

PMID:
29667667
11.

Demethoxycurcumin, a Natural Derivative of Curcumin Abrogates Rotenone-induced Dopamine Depletion and Motor Deficits by Its Antioxidative and Anti-inflammatory Properties in Parkinsonian Rats.

Ramkumar M, Rajasankar S, Gobi VV, Janakiraman U, Manivasagam T, Thenmozhi AJ, Essa MM, Chidambaram R, Chidambaram SB, Guillemin GJ.

Pharmacogn Mag. 2018 Jan-Mar;14(53):9-16. doi: 10.4103/pm.pm_113_17. Epub 2018 Feb 20.

12.

Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease.

Karpenko MN, Vasilishina AA, Gromova EA, Muruzheva ZM, Bernadotte A.

Cell Immunol. 2018 May;327:77-82. doi: 10.1016/j.cellimm.2018.02.011. Epub 2018 Feb 19.

PMID:
29478949
13.

Synthetic 3',4'-Dihydroxyflavone Exerts Anti-Neuroinflammatory Effects in BV2 Microglia and a Mouse Model.

Kim N, Yoo HS, Ju YJ, Oh MS, Lee KT, Inn KS, Kim NJ, Lee JK.

Biomol Ther (Seoul). 2018 Mar 1;26(2):210-217. doi: 10.4062/biomolther.2018.008.

14.

Interleukin 6 and complement serum level study in Parkinson's disease.

Veselý B, Dufek M, Thon V, Brozman M, Királová S, Halászová T, Koriťáková E, Rektor I.

J Neural Transm (Vienna). 2018 May;125(5):875-881. doi: 10.1007/s00702-018-1857-5. Epub 2018 Feb 12.

PMID:
29435648
15.

Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson's Disease in Rats.

Chen G, Liu J, Jiang L, Ran X, He D, Li Y, Huang B, Wang W, Fu S.

Int J Mol Sci. 2017 Dec 21;19(1). pii: E12. doi: 10.3390/ijms19010012.

16.
17.

A low blood copper concentration is a co-morbidity burden factor in Parkinson's disease development.

Ilyechova EY, Miliukhina IV, Orlov IA, Muruzheva ZM, Puchkova LV, Karpenko MN.

Neurosci Res. 2018 Jan 8. pii: S0168-0102(17)30383-8. doi: 10.1016/j.neures.2017.11.011. [Epub ahead of print]

PMID:
29203265
18.

Soy isoflavone genistein attenuates lipopolysaccharide-induced cognitive impairments in the rat via exerting anti-oxidative and anti-inflammatory effects.

Mirahmadi SM, Shahmohammadi A, Rousta AM, Azadi MR, Fahanik-Babaei J, Baluchnejadmojarad T, Roghani M.

Cytokine. 2018 Apr;104:151-159. doi: 10.1016/j.cyto.2017.10.008. Epub 2017 Nov 6.

PMID:
29102164
19.

Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins.

Goes ATR, Jesse CR, Antunes MS, Lobo Ladd FV, Lobo Ladd AAB, Luchese C, Paroul N, Boeira SP.

Chem Biol Interact. 2018 Jan 5;279:111-120. doi: 10.1016/j.cbi.2017.10.019. Epub 2017 Oct 18.

PMID:
29054324
20.

6-Hydroxydopamine induces brain vascular endothelial inflammation.

Fu Q, Song R, Yang Z, Shan Q, Chen W.

IUBMB Life. 2017 Nov;69(11):887-895. doi: 10.1002/iub.1685. Epub 2017 Oct 19.

PMID:
29048735

Supplemental Content

Loading ...
Support Center